FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   ZABRISKIE JOHN L 2. Date of Event Requiring Statement (Month/Day/Year) 01/27/2009 3. Issuer Name and Ticker or Trading Symbol ARCA biopharma, Inc. [ABIO] (Last) (First) (Middle) 207 JUNIPER COURT 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) BASALT, CO 81621 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 29,180 I See Footnote (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	  (2)	08/03/2015	Common Stock	3,887	$ 0.6	D	Â
Option to Purchase Common Stock	  (3)	08/03/2016	Common Stock	5,694	$ 0.9	D	Â
Option to Purchase Common Stock	  (4)	02/02/2017	Common Stock	4,174	$ 1.68	D	Â
Option to Purchase Common Stock	  (5)	05/02/2018	Common Stock	4,174	$ 1.86	D	Â
Option to Purchase Common Stock	  (6)	01/22/2019	Commpn Stock	1,786	$ 5.57	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
ZABRISKIE JOHN L 207 JUNIPER COURT BASALT, CO 81621	  X	Â	Â	Â

Signatures

Patrick Wheeler, attorney in fact		02/05/2009
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	These shares are owned directly by Lansing Brown Investments, LLC. Dr. Zabriskie, one of ARCA's current directors, is the President of Lansing Brown Investments, LLC. Dr. Zabriskie has shared voting and dispositive powers over the shares held by Lansing Brown Investments, LLC. He disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in them
(2)	The options vested as to 971 shares on May 4, 2006; and continue to vest by 242 shares at the end of each quarter thereafter.
(3)	The options vested as to 1,423 shares on August 3, 2007; and continue to vest by 355 shares at the end of each quarter thereafter.
(4)	The options vested as to 1,043 shares on February 2, 2008; and continue to vest by 260 shares at the end of each quarter thereafter.
(5)	The options vest as to 1,043 shares at the end of each quarter following grant date.
(6)	The options are immediately exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.